Tailored Therapy for Helicobacter Pylori Rescue Treatment
NCT ID: NCT03413020
Last Updated: 2018-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2018-01-03
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment
NCT02935010
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
NCT02359331
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
NCT05250050
Helicobacter Pylori Eradication Study
NCT03130452
Rescue Therapy for Helicobacter Pylori Infection
NCT05874544
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tailored Therapy
After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
esomeprazole
proton pump inhibitor
bismuth Potassium Citrate
gastric mucosal protective drug with anti-H. pylori effect
amoxicillin
antibiotic for H. pylori eradication
clarithromycin
antibiotic for H. pylori eradication
metronidazole
antibiotic for H. pylori eradication
levofloxacin
antibiotic for H. pylori eradication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
esomeprazole
proton pump inhibitor
bismuth Potassium Citrate
gastric mucosal protective drug with anti-H. pylori effect
amoxicillin
antibiotic for H. pylori eradication
clarithromycin
antibiotic for H. pylori eradication
metronidazole
antibiotic for H. pylori eradication
levofloxacin
antibiotic for H. pylori eradication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previous failures of H. pylori eradication therapy and need rescue therapy
* Ability and willingness to participate in the study and to sign and give informed consent
* Confirmed H. pylori infection
Exclusion Criteria
* With previous gastric surgery
* Major systemic diseases
* Pregnancy or lactation
* Allergy to any of the study drugs
* Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Lu, MD
Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Lu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, Song Y, Li X, Graham DY, Lu H. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol. 2019 Sep 9;12:1756284819874922. doi: 10.1177/1756284819874922. eCollection 2019.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rjkls2017198
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.